Clinic-pathological features of breast ductal carcinoma in situ with micro-invasion.

Clicks: 251
ID: 81417
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
To investigate the differences of clinic-pathological features among ductal carcinoma in situ (DCIS), ductal carcinoma in situ with micro-invasion (DCIS-MI) and early invasive carcinoma (IDC) in stage T1. From January 2014 to December 2018, 308 cases DCIS, DCIS-MI 92 cases and 111 cases of T1a, 343 cases of T1b, and 1032 cases of T1c were investigated in a retrospective analysis. The population and clinic-pathological characteristics including age, menstrual status, surgical mode, lymph node status and molecular markers were compared in each group. Survival rate of all patients were followed up for 5 years. Compared with DCIS-MI group, the higher breast-conserving rate and lower lymph node metastasis rate in the DCIS group were shown in the DCIS-MI group (P < 0.05). There were no significant differences in tumor diameter, number of tumors, ER, PR, HER2 and Ki67 expression, molecular typing, (P > 0.05). The expression of Ki67 in T1a, T1b and T1c groups increased gradually with elevated grades (P < 0.05). The proportion of HER2-positive patients in DCIS-MI group was significantly higher than that in T1a-b-c (P < 0.05). there were no significant differences in DFS and OS between the 3 groups (P > 0.05). The clinic-pathological features of DCIS-MI are similar to those of DCIS and T1a, but significantly different from T1c.
Reference Key
zheng2020clinicpathologicalcancer Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zheng, Jie;Zhou, Tao;Li, Fang;Shi, Jiajie;Zhang, Lina;
Journal Cancer investigation
Year 2020
DOI
10.1080/07357907.2020.1715422
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.